Latest Healthcare News

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

Wellnex Life Limited is exploring acquisition interest and convertible note funding to accelerate Pain Away's expansion and strengthen its financial footing, signaling a pivotal phase in its turnaround journey.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.